CliffBio
biologic

Granix

tbo-filgrastim

Loss of exclusivityFebruary 2024FDA regulatory exclusivity expiry
CompanyUAB Teva Baltics

Drug detail

Brand nameGranix
Active ingredienttbo-filgrastim
Strength480MCG/0.8ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2012
Marketing statusRx

More from UAB Teva Baltics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Granix patent cliff — loss of exclusivity February 2024 | CliffBio